AU2021327728A1 - (1R,3S)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases - Google Patents

(1R,3S)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases Download PDF

Info

Publication number
AU2021327728A1
AU2021327728A1 AU2021327728A AU2021327728A AU2021327728A1 AU 2021327728 A1 AU2021327728 A1 AU 2021327728A1 AU 2021327728 A AU2021327728 A AU 2021327728A AU 2021327728 A AU2021327728 A AU 2021327728A AU 2021327728 A1 AU2021327728 A1 AU 2021327728A1
Authority
AU
Australia
Prior art keywords
compound
treatment
asthma
use according
eosinophils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327728A
Other languages
English (en)
Inventor
Alina ARIOSA ÁLVAREZ
Juan CAMACHO GÓMEZ
Julio CASTRO- PALOMINO LARIA
Nahomi CASTRO-PALOMINO LARIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palobiofarma SL
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Publication of AU2021327728A1 publication Critical patent/AU2021327728A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2021327728A 2020-08-21 2021-08-20 (1R,3S)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases Pending AU2021327728A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382764.7 2020-08-21
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
AU2021327728A1 true AU2021327728A1 (en) 2023-03-09

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327728A Pending AU2021327728A1 (en) 2020-08-21 2021-08-20 (1R,3S)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Country Status (20)

Country Link
US (1) US20230321053A1 (https=)
EP (2) EP3957308A1 (https=)
JP (1) JP7794807B2 (https=)
KR (1) KR20230054444A (https=)
CN (1) CN115942933A (https=)
AU (1) AU2021327728A1 (https=)
BR (1) BR112023002778A2 (https=)
CA (1) CA3190081A1 (https=)
DK (1) DK4199922T3 (https=)
ES (1) ES3001104T3 (https=)
FI (1) FI4199922T3 (https=)
HR (1) HRP20241621T1 (https=)
HU (1) HUE069338T2 (https=)
LT (1) LT4199922T (https=)
MX (1) MX2023002156A (https=)
PL (1) PL4199922T3 (https=)
PT (1) PT4199922T (https=)
RS (1) RS66263B1 (https=)
SI (1) SI4199922T1 (https=)
WO (1) WO2022038261A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219223A1 (en) 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
KR20160061352A (ko) 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
UA122670C2 (uk) * 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Also Published As

Publication number Publication date
US20230321053A1 (en) 2023-10-12
EP3957308A1 (en) 2022-02-23
RS66263B1 (sr) 2024-12-31
JP2023538419A (ja) 2023-09-07
EP4199922B1 (en) 2024-09-25
DK4199922T3 (da) 2024-11-25
SI4199922T1 (sl) 2025-03-31
HRP20241621T1 (hr) 2025-01-31
KR20230054444A (ko) 2023-04-24
PT4199922T (pt) 2024-12-18
BR112023002778A2 (pt) 2023-03-14
LT4199922T (lt) 2025-01-10
JP7794807B2 (ja) 2026-01-06
CA3190081A1 (en) 2022-02-24
FI4199922T3 (fi) 2024-12-05
HUE069338T2 (hu) 2025-02-28
WO2022038261A1 (en) 2022-02-24
EP4199922A1 (en) 2023-06-28
MX2023002156A (es) 2023-03-01
ES3001104T3 (es) 2025-03-04
CN115942933A (zh) 2023-04-07
PL4199922T3 (pl) 2025-02-10

Similar Documents

Publication Publication Date Title
ES2645368T3 (es) Terapias para mejorar la función pulmonar
TW202128183A (zh) 用於治療多種病症之方法及組成物
US10577414B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
Ohta et al. Japanese guideline for adult asthma
EP4199922B1 (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
Lalloo et al. Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society–2021 update
Massie Exercise-induced asthma in children
US11390671B2 (en) Biopharmaceutical compositions and methods for pediatric patients
CN116033900A (zh) 治疗冠状病毒暴露所致疾病的方法
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
EA048711B1 (ru) (1r,3s)-3-((5-циано-4-фенилтиазол-2-ил)карбамоил)циклопентан-1-карбоновая кислота и ее производные для применения в лечении заболеваний дыхательных путей
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
Szefler Asthma: the new advances
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
TW202539683A (zh) 透過投予(r)-2[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑並[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧雜環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈治療中度至重度氣喘
WO2024015067A1 (en) Methods of administering belumosudil for treatment of chronic graft versus host disease
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
WO2026013001A1 (en) Phosphatidylinositol 4-kinase beta inhibitor compositions for treating human rhinovirus infection
HK40090654A (zh) 右旋普拉克索用於治疗中度至重度哮喘的用途
CN107456455A (zh) 一种预防或治疗炎性疾病的药物组合物
HK1188603B (en) Therapies for improving pulmonary function
HK1188603A (en) Therapies for improving pulmonary function